GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

XBIO · Mar 31, 2024

Xenetic Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001683168-24-003172General Corporate
Operating cash generation62thOwn-history percentile · N=13
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-226.96% · OPTIONAL · VALID

Revenue growth0thOwn-history percentile · N=9
Evidence method

Yoy · gp.fundamentals.revenue

-15.69% · CORE · VALID

Operating margin62thOwn-history percentile · N=13
Evidence method

Level · gp.fundamentals.operating_margin

-248.31% · CORE · VALID

R&D intensity46thOwn-history percentile · N=13
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

184.86% · OPTIONAL · VALID

SBC intensity31thOwn-history percentile · N=13
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

15.09% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History19 statesSelf-history eligible
Period transition

What moved in the state?

Cash Generation Decreased
Previous
-161.98%
Current
-226.96%
Delta
-64.98%
Growth Decreased
Previous
48.80%
Current
-15.69%
Delta
-64.49%
Profitability Decreased
Previous
-177.78%
Current
-248.31%
Delta
-70.53%
R And D Intensity Increased
Previous
137.59%
Current
184.86%
Delta
47.27%
Sbc Intensity Increased
Previous
11.15%
Current
15.09%
Delta
3.94%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.